Transcend Capital Advisors LLC Boosts Stake in Humana Inc. (NYSE:HUM)

Transcend Capital Advisors LLC grew its stake in shares of Humana Inc. (NYSE:HUM) by 399.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,643 shares of the insurance provider’s stock after buying an additional 2,914 shares during the period. Transcend Capital Advisors LLC’s holdings in Humana were worth $924,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of HUM. FNY Investment Advisers LLC grew its holdings in shares of Humana by 6,647.5% during the fourth quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock worth $6,916,000 after buying an additional 26,856 shares in the last quarter. Retirement Systems of Alabama boosted its position in Humana by 735.9% during the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after acquiring an additional 192,801 shares during the last quarter. PDT Partners LLC boosted its position in Humana by 190.0% during the third quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock worth $1,286,000 after acquiring an additional 2,660 shares during the last quarter. Secure Asset Management LLC purchased a new stake in Humana in the 4th quarter worth approximately $244,000. Finally, Ontario Teachers Pension Plan Board raised its holdings in Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after acquiring an additional 71,910 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.32% of the stock is owned by insiders.

Humana Stock Performance

NYSE:HUM opened at $255.77 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm’s 50-day moving average is $269.41 and its 200-day moving average is $290.00. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a market cap of $30.80 billion, a price-to-earnings ratio of 25.71, a PEG ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.38%. Humana’s dividend payout ratio is presently 35.58%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their price target for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Wells Fargo & Company cut their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.